Iopofosine I 131

Phase 3Small molecule

CCellectar Biosciences, Inc.

Iopofosine I 131 is one of 18 small molecule programs targeting B-cell Malignancies. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell MalignanciesActive, not recruiting

Waldenstrom MacroglobulinaemiaNot yet recruiting

B-Cell MalignanciesPhase 2

Active, not recruiting

Waldenstrom MacroglobulinaemiaPhase 3

Not yet recruiting

Competition

Competitive Landscape

26 competitors in B-Cell Malignancies

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

2 2

Brukinsa

BBeOne Medicines

Phase 3

5 3

Fludara

Sanofi

Phase 2

8 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

8 5

Libtayo

Regeneron

Phase 1

1 6

Iopofosine I 131

CCellectar Biosciences, Inc.

Phase 3

1 7

Treanda

AAzurity Pharmaceuticals

Phase 1

1 8

Fabhalta

BBellicum Pharmaceuticals

Phase 1

1 9

Odronextamab

Regeneron

Phase 1

2 10

Parsaclisib

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

B-Cell Malignancies

NCT02952508

Q3 2029

Phase 1Recruiting

Breast Cancer

NCT07311993

Q1 2035

Phase 3Not yet recruiting

Waldenstrom Macroglobulinaemia

NCT07766421

Clinical

Trials by Indication[1]

B-cell Malignancies1 trial

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

Active, not recruiting·CCellectar Biosciences, Inc.·Phase 2·NCT02952508·120 enrolled

Breast Cancer1 trial

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Recruiting·CCellectar Biosciences, Inc.·Phase 1·NCT07311993·60 enrolled

Waldenstrom Macroglobulinaemia1 trial

An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor

Not yet recruiting·CCellectar Biosciences, Inc.·Phase 3·NCT07766421·219 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Iopofosine I 131. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iopofosine I 131 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iopofosine I 131. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cellectar Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCellectar Biosciences, Inc.

Iopofosine I 131

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Q1 2035

Trials by Indication[1]

B-cell Malignancies1 trial

Breast Cancer1 trial

Waldenstrom Macroglobulinaemia1 trial

References

Drug Info

Quick Facts

Related News